Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 2;23(1):500.
doi: 10.3390/ijms23010500.

Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?

Francesco Paolo Russo  1 , Alberto Zanetto  1 , Elisa Pinto  1 , Sara Battistella  1 , Barbara Penzo  1 , Patrizia Burra  1 , Fabio Farinati  1
Affiliations
Review

Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?

Francesco Paolo Russo et al. Int J Mol Sci. .

Abstract

Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related death. Although the burden of alcohol- and NASH-related HCC is growing, chronic viral hepatitis (HBV and HCV) remains a major cause of HCC development worldwide. The pathophysiology of viral-related HCC includes liver inflammation, oxidative stress, and deregulation of cell signaling pathways. HBV is particularly oncogenic because, contrary to HCV, integrates in the cell DNA and persists despite virological suppression by nucleotide analogues. Surveillance by six-month ultrasound is recommended in patients with cirrhosis and in "high-risk" patients with chronic HBV infection. Antiviral therapy reduces the risks of development and recurrence of HCC; however, patients with advanced chronic liver disease remain at risk of HCC despite virological suppression/cure and should therefore continue surveillance. Multiple scores have been developed in patients with chronic hepatitis B to predict the risk of HCC development and may be used to stratify individual patient's risk. In patients with HCV-related liver disease who achieve sustained virological response by direct acting antivirals, there is a strong need for markers/scores to predict long-term risk of HCC. In this review, we discuss the most recent advances regarding viral-related HCC.

Keywords: HBV; HCV; cirrhosis; hepatocellular carcinoma; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. European Association for the Study of the Liver Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018;69:182–236. doi: 10.1016/j.jhep.2018.03.019. - DOI - PubMed
    1. Burra P., Zanetto A., Germani G. Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma. Cancers. 2018;10:46. doi: 10.3390/cancers10020046. - DOI - PMC - PubMed
    1. Pawlotsky J.M., Negro F., Aghemo A., Berenguer M., Dalgard O., Dusheiko G., Marra F., Puoti M., Wedemeyer H., European Association for the Study of the Liver EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol. 2020;73:1170–1218. doi: 10.1016/j.jhep.2020.08.018. - DOI - PubMed
    1. European Association for the Study of the Liver Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 2017;67:370–398. doi: 10.1016/j.jhep.2017.03.021. - DOI - PubMed
    1. Ioannou G.N. Epidemiology and risk-stratification of NAFLD-associated HCC. J. Hepatol. 2021;75:1476–1484. doi: 10.1016/j.jhep.2021.08.012. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources